There are no indications to date of a similar genetic defect in COPD; however, clinical trials are underway in GPP, assessing whether targeting the IL-36R with a blocking monoclonal antibody (Spesolimab) prevents and reverses this disease (26). The gene discussed is IL1RL2; the disease is chronic obstructive pulmonary disease.